Abstract: TH-PO0457
Efficacy of Nefecon in the Treatment of IgAN Complicated by Hepatitis B Virus Infection: A Single-Center Retrospective Study
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Chen, Shasha, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, Sichuan, China
- Li, Guisen, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, Sichuan, China
Background
This study evaluated the efficacy and safety of nefecon in IgA nephropathy (IgAN) patients with hepatitis B virus (HBV) infection, focusing on viral reactivation and hepatotoxicity.
Methods
This single-center retrospective study enrolled 25 IgAN patients with concurrent HBV infection who received nefecon. Mixed-effects models analyzed changes in renal and metabolic parameters. Primary outcome was proteinuria change; secondary outcomes included eGFR change from baseline, HBV viral load, viral reactivation, and hepatotoxicity.
Results
The cohort comprised 25 patients (28.0% female, mean age 40.40±10.86 years). Oxford lesion prevalence: M 60.0%, E 56.0%, S 96.0%, T 44.0%, C 68.0%. All received nefecon plus antiviral therapy. Proteinuria reduced from 1.79±1.19 g/d at baseline to 0.45±0.38 g/d at 9 months (74.9% reduction, P<0.001). eGFR improved from 47.13±23.36 at baseline to 59.45±27.06 mL/min/1.73 m^2 at 9 months (26.1% increase, P<0.001). Urinary erythrocytes declined from 1393.63±3155.46 to 42.00±16.97 cells/HP (P<0.001). Notably, no viral reactivation or significant hepatotoxicity was observed.
Conclusion
Over 9 months, nefecon reduced proteinuria and hematuria, improved renal function, and maintained stable liver function without viral reactivation. Nefecon targets the ileocecal region without affecting systemic immune function, which may confer relative safety in HBV patients.